ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Inventiva

Inventiva (0RNK)

7,62
0,00
( 0,00% )
Aktualisiert: 02:00:00

Inventiva (0RNK) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
7,62
( - )
Gebot
7,62
Fragen
7,62
Volumen
11.643
Durchschnittliches Volumen (3 Mio.)
338.188 €
Finanzvolumen
-
0,00 Tagesbereich 0,00
7,62 52-Wochen-Bereich 7,62
Marktkapitalisierung
Unternehmenswert
939,129M
Handelsende
7,62
Handelsbeginn
-
Letzte Trade
3
@
3.72
(O)
Letzter Handelszeitpunkt
16:00:42
VWAP
-
Erlöse (LTM)
6,76M
Nettogewinn (LTM)
-354,14M
Ausgegebene Aktien
236.280.202
Streubesitz (%)
77,37%
Institutioneller Besitz (%)
71,46%
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-1,8
Kurs-Umsatz-Verhältnis (KUV)
119,52
Gewinn pro Aktie (EPS)
-1,9
Beta
0,89

Über Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome prolifer... Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. Mehr anzeigen

Sektor
-
Branche
-
Hauptsitz
Daix, France
Gegründet
2026
Inventiva is listed in the sector of the Londoner Börse with ticker 0RNK. The last closing price for Inventiva was 7,62 €. Over the last year, Inventiva shares have traded in a share price range of 7,62 € to 7,62 €.

Inventiva currently has 236.280.202 shares in issue. The market capitalisation of Inventiva is 1,80 € billion. Inventiva has a price to earnings ratio (PE ratio) of -1.80.

0RNK Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000DE
40000000DE
120000000DE
26007.627.627.62232247.62DE
52007.627.627.62241507.62DE
156007.627.627.6279257.62DE
260007.627.627.6255217.62DE

0RNK - Frequently Asked Questions (FAQ)

What is the current Inventiva share price?
The current share price of Inventiva is 7,62 €
How many Inventiva shares are in issue?
Inventiva has 236.280.202 shares in issue
What is the market cap of Inventiva?
The market capitalisation of Inventiva is EUR 1,8B
What is the 1 year trading range for Inventiva share price?
Inventiva has traded in the range of 7,62 € to 7,62 € during the past year
What is the PE ratio of Inventiva?
The price to earnings ratio of Inventiva is -1,8
What is the cash to sales ratio of Inventiva?
The cash to sales ratio of Inventiva is 119,52
What is the registered address of Inventiva?
The registered address for Inventiva is 50 rue de Dijon, Daix, Burgundy, 21121
What is the Inventiva website address?
The website address for Inventiva is inventivapharma.com

0RNK Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen